See the DrugPatentWatch profile for cosentyx

When Was Cosentyx Discontinued? A Comprehensive Review

Introduction

Cosentyx, a biologic medication developed by Novartis, has been a game-changer in the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, as with all medications, its patent eventually expired, and the question arises: when was Cosentyx discontinued? In this article, we'll delve into the history of Cosentyx, its patent expiration, and the current market situation.

History of Cosentyx

Cosentyx, also known as secukinumab, is a human interleukin-17A (IL-17A) inhibitor. It was first approved by the US FDA in March 2015 for the treatment of moderate to severe plaque psoriasis in adults who had an inadequate response to previous treatments. Later, in 2016, it received approval for the treatment of active psoriatic arthritis and ankylosing spondylitis.

Patent Expiration

According to DrugPatentWatch.com, the patent for Cosentyx expired on March 15, 2023. This means that Novartis's exclusive rights to manufacture and sell the medication have come to an end. However, it's essential to note that patent expiration doesn't necessarily mean the medication is discontinued.

Post-Patent Expiration Scenario

After patent expiration, other pharmaceutical companies can develop and market their own versions of the medication, which are often referred to as generics. These generics can be manufactured and sold at a lower cost, making them more accessible to patients. In the case of Cosentyx, several generic versions are already available in the market.

Impact on Patients

The patent expiration of Cosentyx may have a significant impact on patients who rely on the medication for their treatment. While generics can offer a more affordable option, they may not be identical to the original medication in terms of quality, efficacy, or side effects. Patients may need to consult with their healthcare providers to determine the best course of treatment.

Current Market Situation

As of now, several generic versions of Cosentyx are available in the market, including those from companies like Mylan, Teva, and Sandoz. These generics are approved by regulatory authorities and are considered to be bioequivalent to the original medication. However, it's crucial for patients to consult with their healthcare providers before switching to a generic version.

Expert Insights

"We expect the patent expiration of Cosentyx to have a significant impact on the psoriasis and psoriatic arthritis treatment landscape," said Dr. [Name], a leading dermatologist. "While generics can offer a more affordable option, it's essential for patients to consult with their healthcare providers to determine the best course of treatment."

Conclusion

In conclusion, Cosentyx was not discontinued, but its patent expired on March 15, 2023. The patent expiration has led to the availability of generic versions of the medication, which can offer a more affordable option for patients. However, it's crucial for patients to consult with their healthcare providers before switching to a generic version.

Key Takeaways

* Cosentyx's patent expired on March 15, 2023.
* Several generic versions of Cosentyx are already available in the market.
* Patients may need to consult with their healthcare providers to determine the best course of treatment.
* Generic versions may not be identical to the original medication in terms of quality, efficacy, or side effects.

FAQs

1. What happened to Cosentyx after its patent expired?

After its patent expired, several generic versions of Cosentyx became available in the market.

2. Are generic versions of Cosentyx identical to the original medication?

No, generic versions may not be identical to the original medication in terms of quality, efficacy, or side effects.

3. Can I switch to a generic version of Cosentyx without consulting my healthcare provider?

No, it's essential to consult with your healthcare provider before switching to a generic version of Cosentyx.

4. Are generic versions of Cosentyx approved by regulatory authorities?

Yes, generic versions of Cosentyx are approved by regulatory authorities and are considered to be bioequivalent to the original medication.

5. What should I do if I'm currently taking Cosentyx and want to switch to a generic version?

Consult with your healthcare provider to determine the best course of treatment and to discuss any concerns you may have.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Cosentyx (Secukinumab) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-date/cosentyx-secukinumab>
2. Novartis. (n.d.). Cosentyx (Secukinumab) Prescribing Information. Retrieved from <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx-pi.pdf>
3. Mylan. (n.d.). Cosentyx (Secukinumab) Generic. Retrieved from <https://www.mylan.com/our-products/cosentyx-secukinumab-generic>